Stone Valerie E, Jordan Jamie, Tolson Jerry, Miller Robert, Pilon Tom
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA.
J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):808-16. doi: 10.1097/00126334-200407010-00007.
Adherence to highly active antiretroviral therapy (HAART) of 95% or greater seems to be required for successful treatment of HIV/AIDS. Efforts to simplify regimens to improve adherence are ongoing, including the advent of once-daily (QD) dosing regimens, which are presumed to be beneficial, although data regarding their overall impact on adherence are not yet available.
To assess patient perceptions of the impact on adherence of 10 attributes of HAART, including QD dosing, and to compare 7 actual regimens based on patients' perceptions of their likelihood to promote adherence.
Two hundred ninety-nine highly treatment-experienced patients with HIV/AIDS completed a questionnaire that evaluated perceptions of the impact on adherence of 10 HAART regimen attributes using a modified adaptive conjoint analysis. Patients' perceptions of the likelihood that they would adhere to 7 actual HAART regimens were scored on Likert scales.
: Pill count, dosing frequency, and adverse events had the greatest impact on patients' perceived ability to adhere to antiretroviral medication regimens. QD was the preferred dosing frequency, but QD dosing regimens did not score better than other regimens. Among actual regimens, predicted adherence was highest for a twice-daily (BID) regimen with 2 pills daily, no dietary restrictions, and 1 prescription and copayment and lowest for a BID regimen with 13 pills daily, food requirements, and 3 prescriptions and copayments.
All HAART regimen attributes studied were perceived to have an impact on adherence, but pill count, dosing frequency, and adverse events had the greatest perceived impact. These data are of potential importance to clinicians as they seek to structure HAART regimens to which their patients are most likely to adhere.
成功治疗HIV/AIDS似乎需要95%或更高的高效抗逆转录病毒疗法(HAART)依从性。目前正在努力简化治疗方案以提高依从性,包括每日一次(QD)给药方案的出现,尽管关于其对依从性的总体影响的数据尚未可得,但据推测该方案有益。
评估患者对HAART的10个属性(包括QD给药)对依从性影响的看法,并根据患者对其促进依从性可能性的看法比较7种实际治疗方案。
299名有丰富治疗经验的HIV/AIDS患者完成了一份问卷,该问卷使用改良的适应性联合分析评估了对10个HAART治疗方案属性对依从性影响的看法。患者对他们坚持7种实际HAART治疗方案可能性的看法用李克特量表评分。
药丸数量、给药频率和不良事件对患者认为坚持抗逆转录病毒药物治疗方案的能力影响最大。QD是首选的给药频率,但QD给药方案的得分并不比其他方案更好。在实际治疗方案中,预测依从性最高的是每日两次(BID)方案,每天2片药,无饮食限制,1张处方和共付费用;最低的是BID方案,每天13片药,有饮食要求,3张处方和共付费用。
所研究的所有HAART治疗方案属性都被认为对依从性有影响,但药丸数量、给药频率和不良事件的影响最大。这些数据对临床医生在构建患者最可能坚持的HAART治疗方案时可能具有重要意义。